Skip to search formSkip to main content

selexipag

Known as: 2-(4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)-N-(methylsulfonyl)acetamide 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Patients with connective tissue disease-associated pulmonary arterial hypertension (PAH-CTD) have a poor prognosis compared with… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2015
2015
Prostacyclin controls cardiovascular function via activation of the prostacyclin receptor. Decreased prostacyclin production… Expand
Is this relevant?
2015
2015
PurposeTargeting the prostacyclin pathway is an effective treatment option for pulmonary arterial hypertension (PAH). Patients… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2015
2015
Selexipag, an orally available, selective IP receptor agonist targeting the prostacyclin pathway, is chemically and… Expand
Is this relevant?
2014
2014
OBJECTIVE The objective of this study was to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2014
2014
The effects of selexipag and its active metabolite ACT-333679 on cardiac repolarization were assessed in a thorough QT study as… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
In this phase 2 proof-of-concept study we examined the safety and efficacy of selexipag, an orally available, selective… Expand
  • table 1
  • table 2
  • figure 1
  • table 4
  • figure 2
Is this relevant?
Review
2012
Review
2012
It is well established that the endothelin, nitric oxide and prostacyclin pathways play an important role in the development of… Expand
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Review
2011
Review
2011
Pulmonary arterial hypertension (PAH) is a severe and debilitating disease characterised by vascular proliferation and… Expand
  • figure 1
  • figure 2
Is this relevant?
2010
2010
Selexipag [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide] is an orally available… Expand
  • figure 1
  • table 1
  • figure 3
  • figure 5
  • figure 6
Is this relevant?